gamcemetinib

Gamcemetinib (BMS-986371) is an orally bioavailable, selective small molecule inhibitor of MAPK-activated protein kinase 2 (MK2), developed by Bristol Myers Squibb. MK2 is a terminal kinase in the p38 mitogen-activated protein kinase (MAPK) signaling pathway, which plays a critical role in the post-transcriptional regulation of pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β). By targeting MK2 rather than p38 MAPK directly, gamcemetinib is designed to achieve potent anti-inflammatory effects while potentially avoiding the toxicity and lack of sustained efficacy often observed with direct p38 inhibitors. It has been investigated in Phase 2 clinical trials for the treatment of chronic inflammatory conditions such as ankylosing spondylitis and rheumatoid arthritis.

Other names

gamcemetinib